You are here

biosimilars

AbbVie’s Humira Loses Only 4% of Market Share to Biosimilars: Report

BioSpace

Tue, 04/9/24 - 11:15 am

Boehringer to lay off salespeople as Humira biosimilar sales lag

Reuters

Fri, 04/5/24 - 11:33 am

Boehringer Ingelheim

Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience

Fierce Pharma

Thu, 04/4/24 - 11:16 am

Teva Pharmaceutical

Drugmaker seeks approval for China's first biosimilar Ozempic

Reuters

Wed, 04/3/24 - 11:07 am

Hangzhou Jiuyuan Gene Engineering

Biden plan would axe interchangeable status for biosimilars

Pharmaphorum

Wed, 03/13/24 - 10:38 am

interchangeability

Fresenius Kabi’s Biosimilar for Actemra Gets FDA Approval

BioSpace

Sun, 03/10/24 - 08:25 pm

Sandoz Nabs FDA Approvals for First Two Biosimilars for Amgen’s Denosumab

BioSpace

Wed, 03/6/24 - 11:29 am

With J&J settlement, Biocon Biologics gets a license to challenge Stelara in the US

Fierce Pharma

Thu, 02/29/24 - 06:57 pm

Biocon Biologics

Samsung joins biosimilar race for Merck & Co.'s Keytruda blockbuster

First Word Pharma

Thu, 02/22/24 - 11:43 am

Samsung Bioepis

clinical trials

Sandoz makes its first post-spinout acquisition

Pharmaphorum

Mon, 01/22/24 - 11:12 am

AbbVie’s Humira Maintains Market Dominance Amid Biosimilar Launches: Report

BioSpace

Thu, 01/18/24 - 11:30 am

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup

Drug Channels

Tue, 01/9/24 - 09:41 am

Express Scripts

CVS to Remove AbbVie’s Humira from Reimbursement Lists, Cover Biosimilars

BioSpace

Thu, 01/4/24 - 10:18 am

Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System

Forbes

Mon, 12/4/23 - 10:14 am

Samsung Bioepis, J&J Ink Settlement and License Deal for Stelara Biosimilar

BioSpace

Thu, 11/30/23 - 11:20 pm

Samsung Bioepsis

FDA Accepts sBLA for Interchangeability Designation for Humira biosimilars

Dermatology Times

Wed, 11/8/23 - 09:55 pm

Samsung Bioepis

Amgen scores FDA approval for Stelara biosimilar

Pharmaceutical Technology

Wed, 11/1/23 - 10:16 pm

AbbVie Stock Dives As Aesthetics Sales Mar Its Third-Quarter Beat And Guidance Boost

Investors Business Daily

Fri, 10/27/23 - 11:51 am

FDA approves Celltrion’s subcutaneous Remicade biosimilar for IBD

Pharm

Mon, 10/23/23 - 05:20 pm

ulcerative colitis

Crohn's Disease

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Reuters

Mon, 10/23/23 - 05:11 pm

Pages